MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.560
-0.010
-0.64%
After Hours: 1.560 0 0.00% 16:00 03/27 EDT
OPEN
1.570
PREV CLOSE
1.570
HIGH
1.735
LOW
1.520
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
4.350
52 WEEK LOW
1.420
MARKET CAP
100.14M
P/E (TTM)
-8.4691
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AFMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AFMD stock price target is 7.26 with a high estimate of 10.37 and a low estimate of 5.19.

EPS

AFMD News

More
  • Affimed Announces Participation at Upcoming Virtual Investor Conferences
  • GlobeNewswire · 3d ago
  • Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
  • ACCESSWIRE · 5d ago
  • Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer
  • GlobeNewswire · 03/17 12:30
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About AFMD

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
More

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.